191 web-programmer-developer-university-of-liverpool Postdoctoral positions at University of Oxford in United Kingdom
Sort by
Refine Your Search
-
Listed
-
Field
-
replication. This post is fixed term for 3 years. What are you going to do? In this fully-funded project, you will: • develop and employ novel advanced biophysical instrumentation based on optical
-
from both technical and policy perspectives. We have an exciting opportunity for a Postdoctoral Researcher to join the programme. The post holder will be responsible for carrying out research in systems
-
the Nuffield Department of Medicine, University of Oxford. GlaxoSmithKline and Oxford University (GO) launched the PRECISE Alliance (Pre-Cancer Biology and Immunoprevention) in 2024, with the aim of conducting
-
team based at the Nuffield Department of Medicine, University of Oxford. GlaxoSmithKline and Oxford University (GO) launched the PRECISE Alliance (Pre-Cancer Biology and Immunoprevention) in 2024, with
-
We are looking to recruit two enthusiastic and motivated Postdoctoral Research Assistants to join the group of Professor Ervin Fodor in the Sir William Dunn School of Pathology at the University
-
associated with the research group of Professor Christopher Yau based in the Big Data Institute at the University of Oxford. The role will involve developing novel artificial intelligence (AI)-based methods
-
therapies. This role offers a unique opportunity to investigate the mechanisms of therapeutic resistance in glioblastoma and contribute to the development of more effective treatment strategies. Our research
-
Novo Nordisk funds a prestigious fellowship programme at the University of Oxford, supporting basic science researchers in diabetes, obesity, cardiovascular diseases, and other cardiometabolic
-
We invite applications for a Postdoctoral Research Assistant to join Pier Palamara’s research group at the University of Oxford. The position is funded by the Pioneer Centre for Statistical and
-
Department of Medicine. Our overarching aim is to develop better prognostic biomarkers to identify patients at particularly high risk of progression from MDS to sAML. We will build on the “liquid biopsy